Unjha Formulations Ltd Upgraded to Sell on Technical Improvement Despite Mixed Fundamentals

Quality Assessment: Weak Long-Term Fundamentals Persist

Despite the upgrade in rating, Unjha Formulations continues to exhibit weak long-term fundamental strength. The company’s operating profits have grown at a modest compound annual growth rate (CAGR) of 15.77% over the past five years, which is below the robust growth levels typically favoured by investors in the Pharmaceuticals & Biotechnology sector. Furthermore, the company’s ability to service its debt remains a concern, with an average EBIT to interest coverage ratio of just 0.54, indicating limited cushion to meet interest obligations from operating earnings.

Quarterly financials for Q3 FY25-26 were flat, signalling no significant improvement in operational performance. This stagnation is reflected in the company’s underperformance relative to the broader market. Over the last year, while the BSE500 index generated a positive return of 2.95%, Unjha Formulations delivered a negative return of -9.47%, underscoring investor caution.

Valuation: Attractive but Reflective of Risks

Valuation metrics present a more positive picture. The company boasts a return on equity (ROE) of 33.1%, which is very attractive and suggests efficient utilisation of shareholder capital. Additionally, the stock trades at a price-to-book (P/B) ratio of 3.1, which is a discount compared to its peers’ historical averages, signalling potential value for investors willing to accept the associated risks.

Interestingly, despite the negative stock price return over the past year, Unjha Formulations’ profits have risen by 41%, resulting in a low price/earnings to growth (PEG) ratio of 0.2. This indicates that the stock may be undervalued relative to its earnings growth, a factor that could appeal to value-oriented investors.

Financial Trend: Flat Quarterly Performance Amid Mixed Long-Term Returns

The company’s recent quarterly results have been flat, with no significant growth in revenues or profits during Q3 FY25-26. This stagnation contrasts with the longer-term trend where operating profits have grown at a moderate pace. However, the stock’s price performance over various time horizons reveals a mixed picture. While Unjha Formulations has delivered impressive returns over three and five years—62.96% and 149.15% respectively—its one-year and year-to-date returns remain negative at -9.47% and -12.00%, respectively.

Comparatively, the Sensex has outperformed the stock over the one-year period, returning -3.48%, and significantly outpaced it over ten years with a 202.64% gain versus the company’s 93.66%. This divergence highlights the stock’s volatility and the challenges it faces in maintaining consistent growth momentum.

Technical Analysis: Key Driver Behind Upgrade

The primary catalyst for the upgrade from Strong Sell to Sell is the improvement in technical indicators. The technical grade has shifted from bearish to mildly bearish, signalling a less negative outlook from a market momentum perspective. Key technical metrics reveal a nuanced picture:

• MACD: Weekly readings have turned mildly bullish, although monthly signals remain mildly bearish, suggesting short-term momentum is improving.
• RSI: Both weekly and monthly relative strength index readings show no clear signal, indicating a neutral momentum stance.
• Bollinger Bands: Weekly bands indicate sideways movement, while monthly bands remain mildly bearish, reflecting limited volatility and a cautious market.
• Moving Averages: Daily averages are mildly bearish, consistent with a cautious near-term outlook.
• KST (Know Sure Thing): Weekly readings are bearish, but monthly readings have softened to mildly bearish.
• Dow Theory: Weekly signals are mildly bullish, contrasting with mildly bearish monthly signals, highlighting short-term optimism amid longer-term caution.

Price action supports this technical improvement, with the stock closing at ₹22.00 on 30 April 2026, up 5.52% from the previous close of ₹20.85. The stock’s 52-week range remains between ₹18.60 and ₹30.40, indicating room for recovery but also reflecting past volatility.

Shareholding and Market Capitalisation

Unjha Formulations is classified as a micro-cap stock, which inherently carries higher risk and volatility. The majority of its shares are held by non-institutional investors, which may contribute to less stable trading patterns and liquidity concerns. This shareholder composition often results in greater price swings and sensitivity to market news.

Investment Outlook: Cautious Optimism Amid Mixed Signals

While the upgrade to Sell from Strong Sell reflects a modest improvement in technical sentiment, investors should remain cautious given the company’s flat recent financial performance and weak debt servicing capacity. The attractive valuation metrics and strong ROE offer some upside potential, but the stock’s underperformance relative to the broader market and mixed technical signals suggest that risks remain elevated.

Investors with a higher risk tolerance may view the current discount to peers and the low PEG ratio as an opportunity to accumulate shares, anticipating a turnaround in fundamentals. However, those seeking stability and consistent growth may prefer to monitor the company’s upcoming quarterly results and debt metrics before committing capital.

Overall, Unjha Formulations Ltd’s rating upgrade is a reflection of improved technical trends rather than a fundamental turnaround, signalling a cautious but slightly more favourable market view.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today